Beam Therapeutics Q2 EPS $(1.08) Beats $(1.42) Estimate, Sales $20.12M Beat $18.05M Estimate
Portfolio Pulse from Benzinga Newsdesk
Beam Therapeutics reported Q2 losses of $(1.08) per share, beating the analyst consensus estimate of $(1.42) by 23.94%. The company also reported quarterly sales of $20.12 million, surpassing the analyst consensus estimate of $18.05 million by 11.45%. This represents a 20.80% increase over sales from the same period last year.
August 08, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Beam Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Beam Therapeutics reported better than expected Q2 earnings and sales. This positive financial performance could increase investor confidence and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100